<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340194</url>
  </required_header>
  <id_info>
    <org_study_id>2016_43</org_study_id>
    <secondary_id>2017-A01822-51</secondary_id>
    <nct_id>NCT03340194</nct_id>
  </id_info>
  <brief_title>Evaluation of Calcinosis in Systemic Sclerosis</brief_title>
  <acronym>CALCIDERMIS</acronym>
  <official_title>Evaluation of Calcinosis Prevalence in Systemic Sclerosis : a Cross Sectional Study Evaluating Calcinosis Cutis Prevalence by Hand and Feet Radiographic Assessment in Systemic Sclerosis Patients and Study Their Correlation With Organ Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis is a rare pathology characterized by fibrosis and vascular lesion with
      skin, pulmonary, digestive and cardiac localisation. Calcinosis cutis is commonly described,
      but its prevalence and appear few documented in literature. Moreover, this studies used
      clinical observation to determine presence or absence of calcification, and rarely
      radiography, in particular for feet localisation. In the same way, skin calcification and
      organ injury association appear unclear. The aim of the study is firstly to determine
      prevalence of calcinosis cutis, with hand and feet radiography realisation in a cohort of
      systemic sclerosis patient. Secondly, will be determine the correlation between calcinosis
      and organ injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calcinosis cutis prevalence by radiographic assessment</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic data</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rodnan score</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral localisation evaluation (cardiac, pulmonary, digestive)</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EUSTAR score</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medsger score</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation (HAQ modified questionary)</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologic vascular markers : VEGF, endothelin 1, endostatin and P/GF, (ELISA method)</measure>
    <time_frame>at inclusion ( baseline)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiography</intervention_name>
    <description>Radiography of the hand and feet (face incident) the day of the inclusion</description>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Veinous punction</intervention_name>
    <description>Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)</description>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Systemic sclerosis patient in the national reference center for scleroderma (Lille, France)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systemic sclerosis presenting ACR-EULAR 2013 criteria

          -  Given their consent

          -  Titulary of health insurance

        Exclusion Criteria:

          -  Dermatomyositis overlap

          -  Pregnant or breastfeeding women

          -  Imprisoned person

          -  Refuse of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent SOBANSKI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent SOBANSKI, MD</last_name>
    <phone>3 20 44 42 95</phone>
    <phone_ext>+33</phone_ext>
    <email>vincent.sobanski@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Claude Huriez, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Sobanski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Calcinosis cutis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

